Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of maraviroc in key subgroups of patients.We analyzed pooled data fro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, Irina Konourina, Andy I. M. Hoepelman, Harry Lampiris, Bernard Hirschel, Pablo Tebas, François Raffi, Benoît Trottier, Nicholaos Bellos, Michael S. Saag, David A. Cooper, Mike Westby, Margaret Tawadrous, John F. Sullivan, Caroline E. Ridgway, Michael W. Dunne, Steve Felstead, Howard Mayer, Elna van der Ryst
Formatua: Artigo
Hizkuntza:ingelesa
Argitaratua: 2008
Sarrera elektronikoa:https://doi.org/10.1056/nejmoa0803154
https://www.nejm.org/doi/pdf/10.1056/NEJMoa0803154?articleTools=true
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

https://doi.org/10.1056/nejmoa0803154
https://www.nejm.org/doi/pdf/10.1056/NEJMoa0803154?articleTools=true

Antzeko izenburuak